• Industry: Pharmaceuticals, Asia Business, China
  • Type: Business and industry issue
  • Date: 6/10/2011

China's pharmaceutical industry – Poised for the giant leap 

Over the next few decades China has the potential to become one of the leaders of the pharmaceutical world. With every big company in the sector focusing on this region as a source of growth, the country is likely to play an increasingly significant role in the way drugs are invented, tested and perhaps even regulated.

Key insights

  • China's booming economy and high GDP growth make its pharmaceutical market the fifth largest and one of the most attractive in the world
  • China's 12th Five-Year Plan focuses on achieving growth through continuous reform and reporting incentives from high-end research to affordable drug pricing
  • The world's top 20 multinational medicine makers have extensive operations in the country, including R&D facilities, joint ventures and wholly owned companies
  • Consolidating the pharmaceutical distribution sector and biotechnology are the focus areas for the next five years
  • A combination of traditional and next-generation advantages is turning China into a haven for outsourcing by pharmaceutical companies.


KPMG’s Pharmaceutical industry practice advises clients with critical business and key industry issues.

Australia-China corridor

Australia-China corridor
The long-term demographic and social forces shaping China and its 12th Five-Year plan will greatly impact Australia's prosperity for decades to come.


Our Australia China Business Practice assists Chinese companies investing in Australia and supports Australian companies investing in China.
  • Subscribe to related feeds